Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer

Qinchuan Wang, Xiyong Liu, Jichun Zhou, Yasheng Huang, Shengjie Zhang, Jianguo Shen, Sofia Loera, Xiaoming Yuan, Wenjun Chen, Mei Jin, Stephen Shibata, Yingbin Liu, Peiguo Chu, Linbo Wang, Yun Yen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives:We aimed to investigate the prognostic value of RRM1 in GC patients.Methods:A total of assessable 389 GC patients with clinicopathological and survival information were enrolled from City of Hope (COH, n = 67) and Zhejiang University (ZJU, n = 322). RRM1 protein expression was determined by immunohistochemistry on FFPE tissue samples. Kaplan-Meier and Cox analyses were used to measure survival. Ras/Raf activity and invasion assays were used to evaluate the role of RRM1 in GC cell lines.Results:In vitro experiments demonstrated RRM1 activated Ras/Raf/MAPK signal transduction and promoted GC cell proliferation. Meanwhile, RRM1 expression was significantly associated with lymph node involvement, tumor size, Ki67 expression, histological subtype and histological grade in the GC tissue samples (p<0.05). Kaplan-Meier analysis illustrated that high RRM1 expression predicted poor survival in GC patients in the COH and ZJU cohorts (log-rank p<0.01). In multivariate Cox analysis, the hazard ratios of RRM1 for overall survival were 2.55 (95% CI 1.27-5.15) and 1.51 (95% CI 1.07-2.13) in the COH and ZJU sets, respectively. In particular, RRM1 specifically predicted the outcome of advanced GCs with poor differentiation and high proliferative ability. Furthermore, inhibition of RRM1 by siRNA significantly reduced the dNTP pool, Ras/Raf and MMP-9 activities and the levels of p-MEK, p-ERK and NF-κB, resulting in growth retardation and reduced invasion in AGS and NCI-N87 cells.Conclusions:RRM1 overexpression predicts poor survival in GC patients with advanced TNM stage. RRM1 could potentially serve as prognostic biomarker and therapeutic target for GCs.

Original languageEnglish
Article numbere70191
JournalPLoS One
Volume8
Issue number7
DOIs
Publication statusPublished - Jul 29 2013

Fingerprint

ribonucleotide reductase
Ribonucleotide Reductases
stomach neoplasms
Stomach Neoplasms
Modulation
Tissue
Signal transduction
Survival
Mitogen-Activated Protein Kinase Kinases
Cell proliferation
Biomarkers
Matrix Metalloproteinases
Small Interfering RNA
Kaplan-Meier Estimate
Tumors
Assays
Hazards
Cells
gelatinase B
small interfering RNA

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer. / Wang, Qinchuan; Liu, Xiyong; Zhou, Jichun; Huang, Yasheng; Zhang, Shengjie; Shen, Jianguo; Loera, Sofia; Yuan, Xiaoming; Chen, Wenjun; Jin, Mei; Shibata, Stephen; Liu, Yingbin; Chu, Peiguo; Wang, Linbo; Yen, Yun.

In: PLoS One, Vol. 8, No. 7, e70191, 29.07.2013.

Research output: Contribution to journalArticle

Wang, Q, Liu, X, Zhou, J, Huang, Y, Zhang, S, Shen, J, Loera, S, Yuan, X, Chen, W, Jin, M, Shibata, S, Liu, Y, Chu, P, Wang, L & Yen, Y 2013, 'Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer', PLoS One, vol. 8, no. 7, e70191. https://doi.org/10.1371/journal.pone.0070191
Wang, Qinchuan ; Liu, Xiyong ; Zhou, Jichun ; Huang, Yasheng ; Zhang, Shengjie ; Shen, Jianguo ; Loera, Sofia ; Yuan, Xiaoming ; Chen, Wenjun ; Jin, Mei ; Shibata, Stephen ; Liu, Yingbin ; Chu, Peiguo ; Wang, Linbo ; Yen, Yun. / Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{f00faabb12fd4241b22a0fa09080a7ff,
title = "Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer",
abstract = "Objectives:We aimed to investigate the prognostic value of RRM1 in GC patients.Methods:A total of assessable 389 GC patients with clinicopathological and survival information were enrolled from City of Hope (COH, n = 67) and Zhejiang University (ZJU, n = 322). RRM1 protein expression was determined by immunohistochemistry on FFPE tissue samples. Kaplan-Meier and Cox analyses were used to measure survival. Ras/Raf activity and invasion assays were used to evaluate the role of RRM1 in GC cell lines.Results:In vitro experiments demonstrated RRM1 activated Ras/Raf/MAPK signal transduction and promoted GC cell proliferation. Meanwhile, RRM1 expression was significantly associated with lymph node involvement, tumor size, Ki67 expression, histological subtype and histological grade in the GC tissue samples (p<0.05). Kaplan-Meier analysis illustrated that high RRM1 expression predicted poor survival in GC patients in the COH and ZJU cohorts (log-rank p<0.01). In multivariate Cox analysis, the hazard ratios of RRM1 for overall survival were 2.55 (95{\%} CI 1.27-5.15) and 1.51 (95{\%} CI 1.07-2.13) in the COH and ZJU sets, respectively. In particular, RRM1 specifically predicted the outcome of advanced GCs with poor differentiation and high proliferative ability. Furthermore, inhibition of RRM1 by siRNA significantly reduced the dNTP pool, Ras/Raf and MMP-9 activities and the levels of p-MEK, p-ERK and NF-κB, resulting in growth retardation and reduced invasion in AGS and NCI-N87 cells.Conclusions:RRM1 overexpression predicts poor survival in GC patients with advanced TNM stage. RRM1 could potentially serve as prognostic biomarker and therapeutic target for GCs.",
author = "Qinchuan Wang and Xiyong Liu and Jichun Zhou and Yasheng Huang and Shengjie Zhang and Jianguo Shen and Sofia Loera and Xiaoming Yuan and Wenjun Chen and Mei Jin and Stephen Shibata and Yingbin Liu and Peiguo Chu and Linbo Wang and Yun Yen",
year = "2013",
month = "7",
day = "29",
doi = "10.1371/journal.pone.0070191",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer

AU - Wang, Qinchuan

AU - Liu, Xiyong

AU - Zhou, Jichun

AU - Huang, Yasheng

AU - Zhang, Shengjie

AU - Shen, Jianguo

AU - Loera, Sofia

AU - Yuan, Xiaoming

AU - Chen, Wenjun

AU - Jin, Mei

AU - Shibata, Stephen

AU - Liu, Yingbin

AU - Chu, Peiguo

AU - Wang, Linbo

AU - Yen, Yun

PY - 2013/7/29

Y1 - 2013/7/29

N2 - Objectives:We aimed to investigate the prognostic value of RRM1 in GC patients.Methods:A total of assessable 389 GC patients with clinicopathological and survival information were enrolled from City of Hope (COH, n = 67) and Zhejiang University (ZJU, n = 322). RRM1 protein expression was determined by immunohistochemistry on FFPE tissue samples. Kaplan-Meier and Cox analyses were used to measure survival. Ras/Raf activity and invasion assays were used to evaluate the role of RRM1 in GC cell lines.Results:In vitro experiments demonstrated RRM1 activated Ras/Raf/MAPK signal transduction and promoted GC cell proliferation. Meanwhile, RRM1 expression was significantly associated with lymph node involvement, tumor size, Ki67 expression, histological subtype and histological grade in the GC tissue samples (p<0.05). Kaplan-Meier analysis illustrated that high RRM1 expression predicted poor survival in GC patients in the COH and ZJU cohorts (log-rank p<0.01). In multivariate Cox analysis, the hazard ratios of RRM1 for overall survival were 2.55 (95% CI 1.27-5.15) and 1.51 (95% CI 1.07-2.13) in the COH and ZJU sets, respectively. In particular, RRM1 specifically predicted the outcome of advanced GCs with poor differentiation and high proliferative ability. Furthermore, inhibition of RRM1 by siRNA significantly reduced the dNTP pool, Ras/Raf and MMP-9 activities and the levels of p-MEK, p-ERK and NF-κB, resulting in growth retardation and reduced invasion in AGS and NCI-N87 cells.Conclusions:RRM1 overexpression predicts poor survival in GC patients with advanced TNM stage. RRM1 could potentially serve as prognostic biomarker and therapeutic target for GCs.

AB - Objectives:We aimed to investigate the prognostic value of RRM1 in GC patients.Methods:A total of assessable 389 GC patients with clinicopathological and survival information were enrolled from City of Hope (COH, n = 67) and Zhejiang University (ZJU, n = 322). RRM1 protein expression was determined by immunohistochemistry on FFPE tissue samples. Kaplan-Meier and Cox analyses were used to measure survival. Ras/Raf activity and invasion assays were used to evaluate the role of RRM1 in GC cell lines.Results:In vitro experiments demonstrated RRM1 activated Ras/Raf/MAPK signal transduction and promoted GC cell proliferation. Meanwhile, RRM1 expression was significantly associated with lymph node involvement, tumor size, Ki67 expression, histological subtype and histological grade in the GC tissue samples (p<0.05). Kaplan-Meier analysis illustrated that high RRM1 expression predicted poor survival in GC patients in the COH and ZJU cohorts (log-rank p<0.01). In multivariate Cox analysis, the hazard ratios of RRM1 for overall survival were 2.55 (95% CI 1.27-5.15) and 1.51 (95% CI 1.07-2.13) in the COH and ZJU sets, respectively. In particular, RRM1 specifically predicted the outcome of advanced GCs with poor differentiation and high proliferative ability. Furthermore, inhibition of RRM1 by siRNA significantly reduced the dNTP pool, Ras/Raf and MMP-9 activities and the levels of p-MEK, p-ERK and NF-κB, resulting in growth retardation and reduced invasion in AGS and NCI-N87 cells.Conclusions:RRM1 overexpression predicts poor survival in GC patients with advanced TNM stage. RRM1 could potentially serve as prognostic biomarker and therapeutic target for GCs.

UR - http://www.scopus.com/inward/record.url?scp=84880799738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880799738&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0070191

DO - 10.1371/journal.pone.0070191

M3 - Article

C2 - 23922955

AN - SCOPUS:84880799738

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e70191

ER -